Literature DB >> 11063589

Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus.

S R Hawtin1, V J Wesley, R A Parslow, S Patel, M Wheatley.   

Abstract

A fundamental issue in molecular pharmacology is to define how agonist:receptor interaction differs from that of antagonist:receptor. The V(1a) receptor (V(1a)R) is a member of a family of related G-protein-coupled receptors that are activated by the neurohypophysial peptide hormone arginine-vasopressin (AVP). Here we define a short subdomain of the N-terminus of the V(1a)R from Glu(37) to Asn(47) that is an absolute requirement for binding AVP and other agonists. In marked contrast to the situation for agonists, deleting this segment has little or no effect on the binding of either peptide or non-peptide antagonists. In addition, we established that this subdomain was crucial for receptor activation and second messenger generation. The oxytocin receptor (OTR) also binds AVP with high affinity but exhibits a different pharmacological profile to the V(1a)R. Substitution of the N-terminus of the V(1a)R with the corresponding sequence from the OTR generated a chimeric receptor (OTR(N)-V(1a)R). The presence of the OTR N-terminus recovered high affinity agonist binding such that the OTR(N)-V(1a)R possessed almost wild-type V(1a)R pharmacology and signaling. Consequently, a domain within the N-terminus is required for agonist binding but it does not provide the molecular discriminator for subtype-selective agonist recognition. Cotransfection and peptide mimetic studies demonstrated that this N-terminal subdomain had to be contiguous with the receptor polypeptide to be functional. This study establishes that a segment of the V(1a)R N-terminus has a pivotal role in the mechanism of agonist binding and provides molecular insight into key differences between the interaction of agonists and antagonists with a peptide receptor family.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063589     DOI: 10.1021/bi0013400

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression.

Authors:  S R Hawtin; A R Davies; G Matthews; M Wheatley
Journal:  Biochem J       Date:  2001-07-01       Impact factor: 3.857

Review 2.  Extramembranous Regions in G Protein-Coupled Receptors: Cinderella in Receptor Biology?

Authors:  Sreetama Pal; Amitabha Chattopadhyay
Journal:  J Membr Biol       Date:  2019-08-30       Impact factor: 1.843

3.  Shift in purine/pyrimidine base recognition upon exchanging extracellular domains in P2Y 1/6 chimeric receptors.

Authors:  Carsten Hoffmann; Kelly Soltysiak; Patrick L West; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2004-11-15       Impact factor: 5.858

Review 4.  Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery.

Authors:  Zhimin Song; H Elliott Albers
Journal:  Front Neuroendocrinol       Date:  2017-10-18       Impact factor: 8.606

5.  Arg-Vasotocin Directly Activates Isotocin Receptors and Induces COX2 Expression in Ovoviviparous Guppies.

Authors:  Li Kang Lyu; Jian Shuang Li; Xiao Jie Wang; Yi Jia Yao; Ji Fang Li; Yun Li; Hai Shen Wen; Xin Qi
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

6.  Molecular variation in AVP and AVPR1a in New World monkeys (Primates, Platyrrhini): evolution and implications for social monogamy.

Authors:  Dongren Ren; Kelvin R Chin; Jeffrey A French
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

7.  SR-BI/CD36 chimeric receptors define extracellular subdomains of SR-BI critical for cholesterol transport.

Authors:  Gabriella A Kartz; Rebecca L Holme; Kay Nicholson; Daisy Sahoo
Journal:  Biochemistry       Date:  2014-09-23       Impact factor: 3.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.